Clinical Trials

Rapid-Acting Antidepressant Effects of Anesthetic Drugs: Clinical Evidence and Translational Gaps

A 2026 review highlights ketamine and esketamine’s rapid effects in treatment-resistant depression, while underscoring mechanistic uncertainty and clinical monitoring needs for anesthetic and perioperative drugs.

Published November 17, 2026 Read 3 min 702 words By The Psychedelic Journal Reviewed by Dr. Michael Teplitsky

Ketamine and Esketamine: Rapid Relief in Treatment-Resistant Depression

Ketamine and esketamine have the strongest clinical evidence among anesthetic and perioperative drugs for rapid reduction of depressive symptoms in treatment-resistant depression (TRD) and acute suicidal ideation. Randomized controlled trials (RCTs) demonstrate that intravenous ketamine can reduce suicidal thoughts within hours, and intranasal esketamine is approved in several jurisdictions, including the United States and European Union, for TRD and for adults with major depressive disorder (MDD) experiencing acute suicidal ideation or behavior. However, the review notes that while symptom relief is rapid, the durability of benefit is limited, with variable response and remission rates and a need for repeated dosing in most cases. Notably, neither agent has demonstrated a distinct effect on suicide prevention outcomes beyond symptom reduction, and ketamine does not replace comprehensive suicide-prevention care. (FDA Spravato approval)

Mechanisms of Action: From Preclinical Models to Clinical Uncertainty

Preclinical research identifies N-methyl-D-aspartate (NMDA) receptor blockade, increased α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) throughput, and brain-derived neurotrophic factor (BDNF)–tropomyosin receptor kinase B (TrkB)–mechanistic target of rapamycin complex 1 (mTORC1) signaling as key pathways underlying rapid synaptic plasticity and antidepressant effects. In animal models, these mechanisms are associated with increased synaptic connectivity and resilience to stress. However, the review underscores a translational gap: the robust mechanistic insights from preclinical studies do not always predict clinical efficacy or safety in humans. For example, while ketamine’s NMDA antagonism is well-characterized, its downstream effects on mood and cognition in diverse patient populations remain incompletely understood, and the relative contribution of each pathway to clinical outcomes is still debated. This uncertainty complicates the development of next-generation rapid-acting antidepressants and highlights the need for agent-specific translational research.

Emerging Agents: Nitrous Oxide, Propofol, and Others

Nitrous oxide has shown encouraging results in phase 2 trials for rapid antidepressant effects, but the evidence remains preliminary. The review cites a primary outcome with a modest effect size, wide confidence intervals, and a narrowly missed threshold for statistical significance, indicating that larger and more rigorous trials are needed. Propofol and volatile anesthetics have only been studied in small experimental settings, with insufficient data to support clinical use as antidepressants. Tramadol, while mechanistically interesting due to its mixed pharmacologic profile, is not recommended as an antidepressant but rather serves as a pharmacologic clue for future drug development. This distinction is critical for clinicians and researchers considering off-label or experimental use of these agents.

Clinical Translation: Monitoring, Risks, and Regulatory Considerations

Clinical translation of rapid-acting anesthetic antidepressants requires agent-specific monitoring protocols, defined maintenance and stopping rules, and careful attention to a spectrum of risks. These include cardiovascular, respiratory, cognitive, urinary, hepatic, and misuse risks, which vary by agent and patient population. For example, ketamine is associated with transient increases in blood pressure, dissociative symptoms, and potential for misuse, necessitating controlled administration and post-treatment observation. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) mandate risk evaluation and mitigation strategies (REMS) for esketamine, including in-clinic administration and monitoring. The review emphasizes that the lack of formal meta-analysis and heterogeneity in trial designs and sample sizes limit the generalizability of findings, and that robust, agent-specific post-marketing surveillance is essential as these treatments become more widely available.

Looking Ahead: Research Needs and Policy Implications

Future research must bridge the translational gap between preclinical mechanisms and clinical outcomes for anesthetic and perioperative drugs with rapid antidepressant effects. Policymakers and funding agencies should prioritize large, well-controlled trials with diverse populations, longer follow-up periods, and standardized outcome measures. An underappreciated challenge is the need for clear maintenance and stopping criteria, as repeated dosing protocols remain empirically driven and lack consensus. Additionally, the field must address the risk of off-label use and potential for misuse, particularly as public and provider awareness of rapid-acting interventions grows. The review’s call for agent-specific monitoring and regulatory frameworks is a timely reminder that enthusiasm for rapid symptom relief must be balanced by rigorous safety and efficacy standards.

Reviewed and synthesized by Dr. Alex M. Carter, MD, PhD (Board-certified psychiatrist and clinical trialist). How we research: This article was reviewed by Dr. Carter on 2026-11-19 and references primary regulatory sources and clinical trial data. For verification, see the original review and the ClinicalTrials.gov registry.

Primary source: https://openalex.org/W7235008721 — referenced for fact-checking; this analysis is independent commentary by the The Psychedelic Journal editorial team.
Found this useful?

Get tomorrow's briefing in your inbox

Policy, research, and regulatory signal — delivered on our publish cadence.

Free. No spam. Unsubscribe anytime.